Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last €40.12 EUR
Change Today +0.63 / 1.61%
Volume 0.0
NK8 On Other Exchanges
As of 10:58 AM 05/4/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

7475 Lusk Boulevard

San Diego, CA 92121

United States

Phone: 858-909-1800

Fax: 800-475-9134

NuVasive, Inc., a medical device company, focuses on developing minimally disruptive surgical products and procedurally integrated solutions for the spine. The company’s product portfolio is focused on applications for spine fusion surgery, including biologics. The company’s principal product offering includes a minimally disruptive surgical platform called Maximum Access Surgery (MAS). The MAS platform combines three categories of solutions that collectively minimize soft tissue disruption during spine fusion surgery, provide maximum visualization and are designed to enable safe and reproducible outcomes for the surgeon and the patient. The platform includes the company’s proprietary software-driven nerve detection and avoidance systems, NVM5 and NVJJB, and Intra-Operative Monitoring (IOM) support; MaXcess, an integrated split-blade retractor system; and various specialized implants. The individual components of the company’s MAS platform, and many of its products, can also be used in open or traditional spine surgery. The company’s spine surgery product line offerings, which include products for the thoracolumbar and the cervical spine, are primarily used to enable access to the spine and to perform restorative and fusion procedures in a minimally disruptive fashion. Its biologic product line offerings used to aid the spinal fusion process or bone healing include allograft (donated human tissue), Osteocel Plus, an allograft cellular matrix containing viable mesenchymal stem cells, or MSCs, FormaGraft, a collagen synthetic product, and AttraX, a synthetic bone graft material, available commercially only in select markets outside of the U.S. The company’s subsidiary, Impulse Monitoring, Inc. (Impulse Monitoring) provides IOM services for insight into the nervous system during spine and other surgeries. The company’s MaXcess instruments provide access to the spine in a manner that affords direct visualization and its nerve monitoring systems assist surgeons in the detection and avoidance of critical nerves. The company’s cervical product offering provides a set of solutions for cervical fusion surgery, including both allograft and CoRoent implants, as well as cervical plating and posterior fixation products. Strategy The company pursues the following business strategies in order to improve its competitive position: establish MAS Platform as the Standard of Care; continue to develop and introduce procedurally integrated solutions and new innovative products; expand the reach of exclusive sales force; provide tailored solutions in response to surgeon needs; selectively license or acquire complementary spine products and technologies; and provide IOM capabilities. The NuVasive Solution — MAS with minimal tissue disruption The company’s MAS platform allows surgeons to perform a range of minimally disruptive spine procedures in all regions of the spine and from various surgical approaches, while overcoming the shortcomings of traditional minimally invasive spine surgical techniques. The MAS platform is designed to treat a range of spinal pathologies while accommodating a surgeon's preferred surgical technique and is not limited to a single approach. The company’s MAS platform combines three product categories: its nerve monitoring systems, MaXcess and specialized implants. Its nerve monitoring systems enable surgeons to detect and navigate around nerves while MaXcess affords direct customized access to the spine for implant delivery. MaXcess also allows surgeons to use traditional instruments in a minimally disruptive and less traumatic manner while its biologics offering complements its MAS platform by facilitating bone growth and thereby fusion. The company also offers various specialized implants that enable the maximization of disc height restoration and structural support while conforming to the anatomical requirements of the patient. The company’s products facilitate minimally disruptive applications of the following spine surgery procedures, among others: lumbar and thoracic fusion procedures in which the surgeon approaches the spine through the patient’s back, side or abdomen; cervical fusion


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NK8:GR €40.12 EUR +0.63

NK8 Competitors

Market data is delayed at least 15 minutes.

Company Last Change
CONMED Corp $51.56 USD +1.40
Globus Medical Inc $23.87 USD +0.57
Integra LifeSciences Holdings Corp $65.93 USD +0.45
Masimo Corp $34.39 USD +0.22
Thoratec Corp $40.34 USD +0.20
View Industry Companies

Industry Analysis


Industry Average

Valuation NK8 Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 2.8x
Price/Book 3.3x
Price/Cash Flow NM Not Meaningful
TEV/Sales 1.9x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NUVASIVE INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at